Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus.
OBJECTIVE
To assess the effect of a strict control of modifiable cardiovascular risk factors on coronary risk (CR) in patients with type 2 diabetes mellitus (T2DM) in clinical practice.


METHODS
Longitudinal, open and observational study in 530 patients with T2DM. Fasting plasma glucose (FPG), glycated haemoglobin (HbA 1C), postprandial capillary glucose (PCG), total cholesterol, high-density lipoprotein-cholesterol, triglycerides, systolic (SBP) and diastolic (DBP) blood pressure were measured; low-density lipoprotein-cholesterol and body mass index were calculated; and 10 years CR was predicted before and after 6 months of therapy implementation. The percentage of patients who reached the targets, according to published guidelines, and the use of insulin and various cardioprotective medications were compared before and after therapy implementation.


RESULTS
There was a significant decrease in mean HbA 1C, FPG, PCG, total cholesterol, triglycerides, SBP, DBP, and CR after intervention. The percentage of patients who reached the HbA 1C, FPG, PCG, total cholesterol, triglycerides, SBP, DPB, and CR targets, and the number of subjects taking insulin and cardioprotective drugs increased significantly after intervention.


CONCLUSIONS
This study shows that a strict control of modifiable cardiovascular risk factors in patients with T2DM in clinical practice has a beneficial effect over predicted CR.
del Cañizo Gómez
Francisco Javier
FJ
Unidad de Endocrinología, Hospital Virgen de la Torre, Madrid, España. fjcanizo@arrakis.es
Moreira Andrés
María Natividad
MN
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors; D000886:Anthropometry; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D012307:Risk Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D007328:Insulin